RCAG
UTMD icon

Rehmann Capital Advisory Group’s Utah Medical Products UTMD Stock Holding History

Rehmann Capital Advisory Group’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$28.8K Hold
300
– – ﹤0.01% 773
2019
Q2 		$28.7K Buy
+300
New +$25.3K ﹤0.01% 1035
2019
Q1 		– Sell
-300
Closed -$24.9K – 2147
2018
Q4 		$24.9K Buy
+300
New +$26.4K ﹤0.01% 802

Other funds holding UTMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $67.5B AUM 28.09% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rehmann Capital Advisory Group's UTMD Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Utah Medical Products (UTMD) position steady in Q3 2019 at 300 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #773.

Rehmann Capital Advisory Group first reported a position in UTMD in Q4 2018 and has held it in 3 quarters since. 97 funds tracked by Wall St. Rank hold UTMD as of Q3 2019.

  • Rehmann Capital Advisory Group held 300 shares of Utah Medical Products worth $28.8K as of Q3 2019.
  • Rehmann Capital Advisory Group left its Utah Medical Products share count unchanged in Q3 2019.
  • Utah Medical Products made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #773 holding.
  • Rehmann Capital Advisory Group first reported a position in Utah Medical Products in Q4 2018 and has held it in 3 quarters since.
  • 97 funds tracked by Wall St. Rank held Utah Medical Products as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.